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heAmericanDiabetesAassociation’s
57th Annual Advanced Postgradu-
ate Course was held 5–7 February
2010 in San Francisco, California. Free
webcasts of the talks from the 57th
Annual Advanced Postgraduate Course
are available at http://professional.
diabetes.org/pg10.
Risk prediction in diabetes
Michael Stern (San Antonio, TX) dis-
cussed risk prediction in diabetes, ad-
dressing the use of biomarkers and
approaches with risk calculation engines.
In general, he noted, the state of wellness
is inherently asymptomatic without func-
tional impairments, and many individual
with diagnosed diabetes, hypertension,
and even with cardiovascular disease
(CVD) are “well.” For these individuals,
treatment provides no current beneﬁt but
only the promise of a future beneﬁt,
which may never come to pass. If a well
person in this sense cannot be made bet-
ter, Stern pointed out that we must be
particularly cognizant of the dictum as-
cribed to Niels Bohr: “Prediction is very
difﬁcult, especially about the future.”
A tool used in analysis of tests is the
calculation of the area under the curve
(AUC) of the receiver-operating charac-
teristic graph of sensitivity versus (1-
speciﬁcity). The AUC can be interpreted
to equal the likelihood that a person des-
tined to develop the disease or character-
istic being tested for has a higher score,
comparing one person who is with an-
other who is not going to develop the
given outcome (1). The AUC should be
contrasted with an odds ratio (OR) or rel-
ative risk, which may be calculated as
equaling (sensitivity)  (1  false posi-
tive rate)/[(1  sensitivity)  (false posi-
tive rate)]. This may better be thought of
as pertaining to populations, with an OR
of 1.5–3.0 giving rise to AUCs of 0.57–
0.68, which Stern termed not terribly im-
pressive levels, as can be observed in the
overlapofdistributioncurvesofthosede-
veloping versus not developing the dis-
ease or characteristic. An OR of 10 is
needed to give a reasonable AUC of 0.83
and, hence, to distinguish individuals,





tolic blood pressure, BMI, and family his-
tory (2). The AUC is 0.85 for this model,
a level higher than that seen with the fast-
ingorthe2-hpostglucoseloadbloodglu-
cose alone. Stern commented also that
impaired fasting glucose (IFG) and im-
paired glucose tolerance (IGT) are given
as ﬁxed points, while this (or any) predic-
tive equation gives a range of values
whose cut point can be set at whatever
level seems appropriate for a given popu-
lation. A recently proposed approach is
the commercially available Tethys assay,
which gives a diabetes risk score (DRS)
using fasting glucose, 2-h insulin, adi-
ponectin, ferritin, interleukin-2 receptor
, C-reactive protein, and, in some appli-
cations,A1C.TheDRShasbeenvalidated
based on the Inter99 study of 6,794
Danes (3) and the Botnia study of 1968
Finnish and Swedish subjects (4), with 5-
and 15-year follow-up, respectively. The
score ranges from 1–10 and low risk is
considered 4.5, moderate 4.5–8, and
high 8. Stern illustrated the use of the
DRS by reviewing its contribution to risk
assessment in those with IFG, whose 9%
risk of developing diabetes exceeds by up
to 2% the risk of those with NFG. Among
the IFG group, those with low DRS (com-
prising 26% of the group) have 2% risk,
those with moderate risk (53%) have 7%,
and the 21% with high-risk DRS scores
have 24% risk of converting to diabetes
over 5 years, suggesting that clinically
useful additional information can be
gainedfromthisapproach(3).Inasimilar
analysis, the 25% of the population with
metabolic syndrome had an overall 8%
risk,whilethoseremaininghad2%riskof
developing diabetes. Stratifying those
with metabolic syndrome, the 23% with
low DRS had 2% diabetes risk, the 54%
with moderate DRS had 6% diabetes risk,
and the 23% with high DRS developed
diabetes at a 23% rate. Thus, risk models
are more potent than dichotomous
measures such as IFG and metabolic
syndrome and, hence, “contain more in-
formation about the future.” The AUC for
the DRS is similar to that of the Stern risk
model at a bit over 0.8, suggesting that a
clinical score (inexpensive, in the sense
that ascertainment of data by clinicians is
considered to be “free”) would have sim-
ilar beneﬁt to the Tethys test.
Why, Stern asked, should we bother
with risk prediction scores? How is the
information to be used? Certainly, one
can more aggressively treat blood pres-
sure and lipids, but he commented, “you
don’t really need a diabetes risk score” for
this. The reason, rather, is precisely to
prevent diabetes and, more importantly,
by doing so to prevent its complications.
“We know that we can prevent diabetes,”
as the Finnish Diabetes Prevention Study,
the Da Qing Diabetes Study, the Diabetes
prevention program, Tripod, DREAM,
and Act-Now have shown. “I am of the
opinion,” Stern continued, “that we really
need studies that show an impact on hard
end points.” Surrogate measures such as
glucose, blood pressure, coronary Ca
,
and carotid IMT “can have abnormal val-
ues [while the person is] ‘well.’” Actual
morbidities to be prevented are death,
heart attack, stroke, end-stage renal dis-
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Stern said, “I reserve the right to remain
skeptical.”Itis,hesaid,possiblethatwait-
ing for diabetes to develop might be ade-
quateifaggressivetreatmentmeasuresare
then employed. The long-term Diabetes
Prevention Program (DPP) Outcomes
Study is under way (5), he added, and
“whether or not it will give deﬁnitive in-
formation we shall see.”
A related issue is whether screening
should be done to identify diabetes itself
at an earlier stage. Again, Stern said, we
need to demonstrate beneﬁts of early as
opposed to delayed treatment. The con-
servative approach would be to wait until
diabetes presents, more aggressive would
be to screen, and most aggressive would
be to predict. ADA Position Statements in
thepasthavesuggestedthatscreeningbe-
gin at age 45 years and be carried out ev-
ery 3 years, particularly for those with
BMI 25 kg/m
2 (6), but Stern wryly ob-
served that such recommendations are
“not exactly data driven,” and the current
ADA guidelines, although discussing the
approach to the person who is found to
have “pre-diabetes,” are silent on how
such ascertainment should be carried out
(7). The U.S. Preventive Services Task
Force recommends screening for individ-
uals with blood pressure 135/80
mmHg, as treatment recommendations
are different if diabetes is present, but
Stern noted that this, too, is not data
driven. Using the Archimedes Model, a
simulation study compared health out-
comes with eight different diabetes
screening strategies, starting at age 30
years every 3 years; at age 45 years every
1, 3, and 5 years; at age 60 years every 3
years, at the time of hypertension diagno-
sis, just once, or every ﬁve visits; or, the
maximal strategy, beginning at age 30
years and then repeating every 6 months.
In all cases, treatment to achieve recom-
mended glucose, blood pressure, and
lipid levels, taking into account known
information about compliance, was used
in predicting outcome (8). Without
screening, diabetes was present in 15%
of individuals at age 56 years, 20% at age
67 years, and so on. All the strategies pre-
vented 2–5 deaths per 1,000 people (of
250 deaths per 1,000 individuals), pre-
vented 3–9 myocardial infarctions of
150, and prevented 3–9 microvascular
complications of 120, with little effect on
stroke. “The effects of this are modest,”
Stern concluded, “let’s face it,” although
the study did ﬁnd that screening for type
2 diabetes is cost-effective when started
between ages 30–45 years and repeated
every 3–5 years, at a cost of $10,000–
15,000 per quality-adjusted life year
(QALY); most cost-effective was screen-
ing hypertensive individuals annually, at
$6,287/QALY.
Vitamin D and diabetes
Neil Binkley (Madison, WI) discussed vi-
tamin D, whose deﬁciency may contrib-
ute to the pathogenesis, prevention, and
treatment of diabetes. A serum 25-
hydroxyvitamin (25-OH) D level of 40
ng/ml appears appropriate but requires
ingestion of 2000–4,000 IU daily. Vita-
min D is produced from 7-dehydro-
cholesterol, which forms pre-D3 on
exposure to ultraviolet light; Binkley
notedthatfewfoodshavevitaminD,with
cod liver oil having 1,360 IU vitamin D
per tablespoon but also containing huge
amounts of vitamin A, which can cause
bone loss, making this not a useful ap-
proach. Rickets was ﬁrst described by
Whistler in the 1600s in England, and by
the late 1800s it affected a substantial
number of children in Europe. The dis-
coverythatradiationoffoodcuredrickets
led to elimination of the disease in the
U.S., although it does occur in breast-fed
infants, particularly of vitamin D–deﬁ-
cient African American women. Few
foods, however, are sufﬁciently fortiﬁed
to achieve currently recommended
25-OH D levels, for which one would
need to drink 10–40 glasses of milk daily
(9). “We’re indoors,” Binkley said, “we
wear sunscreen, we wear clothes...with
advancing age our skin becomes less able
to make vitamin D.” There is progressive
worsening of vitamin D status with age
(10) and with increasing degrees of obe-
sity (11), leading Binkley to speculate as
to whether vitamin D deﬁciency might be
a cause rather than a consequence of in-
creased body weight.
25-OHDmaybeconsideredthestor-
age form of the vitamin, with circulating
levels of 1,25 regulated. Vitamin D deﬁ-
ciency upregulates parathyroid hormone
(PTH),increasingrenal1-hydroxylation
of vitamin D, so 1,25 di-hydroxy-vitamin
D measurement is only useful in individ-
uals with renal disease. Vitamin D deﬁ-
ciency is considered to occur with 25-OH
Dlevels10.Sufﬁciencyisconsideredby
U.S. groups to require levels 30 ng/ml
(12), although Binkley pointed out that
the European recommendation is for lev-
els20ng/ml.Basedontherelationship
betweenvitaminDandPTHasamarker
of bone health, it may be that the opti-
mal25-OHDvariesbysystem,withop-
timallevelsforboneandskeletalmuscle
38–40, while periodontal and cancer
prevention requirements may be lower
(13). The Institute of Medicine Food
andNutritionBoardiscurrentlyreview-
ing dietary reference intakes for vitamin
D, and Binkley suggested that they
probably will recommend 800–1,000
IU/day, which Binkley termed “conser-
vative,” noting that to achieve levels
30 ng/ml for 97.5% of individuals a
daily intake of 2,600 IU is required
(14). Both forms of the vitamin, D3 and
D2, are effective, and in the U.S. the
high-dose 50,000 unit prescription tab-
lets are only available as D2. Both forms
appear to be similar in curing Rickets in
older studies (15), but vitamin D2 has
shorter duration of activity (16) and vi-
tamin D3 may be slightly more potent
(17). Binkley reviewed his studies
showing that 25-OH D measurement is
very laboratory speciﬁc (18), although
the measurement has improved and ref-
erence materials are now available, but
he recommended, “if you’re aiming to
be above 30 ng/ml, aim for 40.” The test
is rather expensive, costing $100, a
prohibitive $30 billion expense if
done on all Americans. He recom-
mended its measurement in patients
with osteoporosis, increased risk of fall-
ing, malabsorption, and perhaps those
with malignancies and those with
diabetes.
Binkley stated that vitamin D levels
30 ng/ml are safe, with no effect on se-
rum or 24-h urine calcium (19–21). Vi-
tamin D intoxication, Binkley said,
requires ingestion of 10,000, and per-
haps 40,000 units daily, with each ad-
ditional1,000unitsincreasingcirculating
25-OH D by 6 ng/ml (22). The usual
25-OHDlevelinindividualsintenselyex-
posed to sunlight is 60–80 ng/ml (23).
This shows considerable variability, with
Binkley describing a study of surfers in
Hawaii whose 25-OH D ranged from 10
to65ng/ml.Particularlylowerlevelswere
seeninthoseofAsianethnicity.Giventhis
variability, one should be careful in rec-
ommending replacement doses. Binkley
suggested that individuals with screening
levels 30–40 ng/ml should have a daily
1,000IUsupplementthatat20–30ng/ml
a 2,000 IU supplement be used, and that
those with levels 20 ng/ml receive a
prescriptiondoseof50,000IUweeklyfor
8 weeks or 50,000 IU three times weekly
for 4 weeks. Food fortiﬁcation might be
an effective population approach, but
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this.Itisnoteworthythatintracellular1-
hydroxylation of vitamin D occurs in
many tissues (24), leading to a variety of
autocrine/paracrine nonclassical effects.
Higher levels of vitamin D are associated
with lower risks of malignancy (25), and
vitamin D appears both to improve -cell
function and insulin action (26). Numer-
ous epidemiologic studies show associa-
tion of low vitamin D levels and of lack of
supplementation with higher rates of de-
velopment of diabetes (27–30). The dose
used is important, with no beneﬁt found
from administration of calcium plus 400
IUvitaminDdailyintheWomens’Health
Initiative (31) or with an 800 IU daily
dose in RECORD (32).
Fascinating studies show that at lati-
tudes near the equator type 1 diabetes in-
cidence is lower (33), and Finn children
supplemented as infants had much lower
type 1 diabetes risk, while those who de-
veloped rickets had higher risk (34,35).
There is also evidence that vitamin D re-
duces risk of macular degeneration (36),
of development of renal disease both in
animal models (37) and in human popu-
lation studies (38), of myocardial infarc-
tion (39), and of mortality (40), although
Binkley cautioned that low vitamin D sta-
tusmaybeasurrogateforillnessorsocio-
economic factors, which could explain
the epidemiologic associations.
Cardiometabolic risk and polycystic
ovary syndrome
Andrea Dunaif (Chicago, IL) noted that
the major factors giving rise to polycystic
ovarysyndrome(PCOS)aremetabolic,in
association with insulin resistance and
obesity, with the consequent develop-
ment of hyperandrogenemia and anovu-
lation affecting 7% of premenopausal
women. An additional 5–20% of pre-
menopausal women have hyperandro-
genemia, which increases with obesity
and may contribute to premenopausal
cardiovascular risk. PCOS is present in
25% of type 2 diabetic women, while
anovulation and high androgen levels
identifywomenatparticularriskofdevel-
opingdiabetes.Theriskoftype2diabetes
increases among adolescent and young
adult women with PCOS (41), with obe-
sity further increasing risks of diabetes
and of hypertriglyceridemia (42). Ovar-
ian function abnormality is, then, neces-
sary for the diagnosis of PCOS. It is
noteworthy that longer menstrual cycle
length is associated with diabetes risk
(43). Insulin resistance is seen in lean as
well as in obese women with PCOS (44),
with thiazolidinedione administration
improving this (45). PCOS, obesity, and
cardiometabolic risk factors are, Dunaif
pointed out, closely correlated, and she
notedthattestosteronealsoworsensthese
factors and that administration of the an-
tiandrogen ﬂutamide was shown to re-
duce visceral fat and increase insulin
sensitivity (46).
PCOS has a strong genetic compo-
nent, Dunaif stated, having high correla-
tion(r	0.71)inmonozygotictwins.She
noted that 40% of sisters of women with
PCOS have features of the syndrome and
elevated testosterone, with brothers of
women with PCOS having elevated dehy-
droepiandrosterone levels (47). Meta-
bolic syndrome aggregates in families of
women with PCOS (48,49), while in ani-
mal models prenatal androgen adminis-
tration produces a metabolic syndrome
phenotype (50).
Coronary artery calcium levels are in-
creased in PCOS (51), although it is
noteworthy that women with hyperan-
drogenemia but normal ovaries and ovu-
lation do not appear to have increased
cardovascular risk and not all epidemio-
logic studies have shown increased coro-
nary artery disease risk in young women
withthesyndrome(52).Irregularmenses
are, however, associated with higher car-
diovascular risk (53), and there is evi-
dence of increased mortality among
women with PCOS (54). An important
therapeutic question is whether oral con-
traceptiveshaveadversemetabolicconse-
quences. There may be adverse effect of
such agents containing cyproterone, but
no adverse effect has been seen with low-
dose estrogen preparations (55) or with
the very commonly used preparation
ethenyl estradiol/drosipirenone, which
may nave antiandrogenic effects (56).
Metformin (57) appears to have cardio-
vascular as well as metabolic beneﬁt in
PCOS,andinterestingly,thereisevidence
of endocrine as well as lipid beneﬁt of
simvastatin in the condition (58).
Obstructive sleep apnea and
diabetes
Esra Tasali (Chicago, IL) discussed asso-
ciations between obstructive sleep apnea
(OSA) and type 2 diabetes. OSA is a con-
dition of recurrent collapse of the upper
airway during sleep, resulting in reduc-
tions in oxygen staturation and transient
arousal, typically not remembered by the
individual. OSA is associated with obe-
sity, particularly central; age; male sex;
and the phenotype of enlarged tongue,
soft palate, uvula, and tonsils, with in-
creased neck circumference, reducing the
upper-airway cross-sectional area. Alco-
hol and sedative and antihistamine use
are additional causes. The condition may
not be associated with speciﬁc nocturnal
symptomsormaybeassociatedwithnoc-
turnal snoring, choking, restlessness,
sweating, and esophageal reﬂux, and be-
cause of the recurrent arousal may be a
common cause of nocturia. The diagnosis
is by sleep study with polysomnography,
with the apnea/hypopnea index the num-
ber of such episodes occurring hourly
during sleep; 5 is normal, and 5–14,
14–29, and 30 are considered to repre-
sent mild, moderate, and severe OSA, re-
spectively. The treatment most often
recommended is continuous positive air-
way pressure (CPAP), which acts as a
splint to prevent upper-airway collapse,
but despite the development of various
face masks and nasal cannulae and de-
vices that are smaller, humidiﬁed, and
quieter, compliance with use of this treat-
mentispoor,withpatientsonaverageus-
ing CPAP less than half of the time
recommended. Oral appliances to bring
the jaw forward are helpful.
There is evidence that OSA is linked
to CVD and diabetes, in part indirectly
from the association of obesity, hyperten-
sion,cigaretteuse,andothercardiovascu-
larriskfactorswithOSAaswell,butthere
is evidence that OSA is related to insulin
resistance and diabetes risk. The preva-
lence of OSA in type 2 diabetic individu-
als has variously been reported at 58%
(59), 71% (60), and 86% (61). Further-
more, the degree of severity of OSA is, in
patientswithdiabetes,associatedwiththe
A1C level (62). Interestingly, one of the
mechanisms of the association of PCOS
with insulin resistance may involve OSA
(63). Conceptually, both fragmentation
of sleep and the intermittent hypoxemia
caused by OSA may lead to increased
sympathetic activity, activation of the hy-
pothalamic-pituitary-adrenal axis, and
the elaboration of proinﬂammatory cyto-
kines from adipocytes and other cell
types. If OSA causes diabetes and, in dia-
betic individuals, increases the blood glu-
cose, Tasali asked, might treatment of
OSA improve glycemia? A study of 25 di-
abetic individuals showed CPAP to re-
duce A1C and, on continuous glucose
monitoring, postprandial glycemia (64).
Few prospective or interventional studies
have been carried out, however, and
many other studies have had negative re-
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sample sizes and poor compliance with
CPAP, with those studies reporting this
measure suggesting fewer than half of the
expected hours of use of the devices.
Tasali reviewed several studies that
she has carried out. In an experimental
model of OSA in which healthy volun-
teerswerearousedwithloudnoiseswhen
they entered deep (stage 4) sleep, leading
tounchangedtotalsleepduration,insulin
sensitivity decreased 25%, with spectral
analysisofheartratevariabilitysuggesting
increased sympathetic tone. A 5-day pe-
riodofsleepdeprivationcausedabnormal
glucose tolerance with decreased insulin
secretion. Interestingly, there is evidence
that sleep deprivation increases measures
of inﬂammation. Comparing 22 individ-
uals with habitual short sleep times (aver-
aging 5.25 h) with 22 normal sleepers
(averaging 7.8 h nightly), glucose toler-
ance was normal but with increased
insulinsecretion,suggestinginsulinresis-
tance. Sleep deprivation may alter appe-
tite regulation, reducing levels of leptin
and increasing ghrelin and leading to in-
creased appetite, with increases in self-
reported appetite and in preference for
carbohydrate in such a setting (65). Sleep
loss, then, may contribute to the develop-
ment of diabetes, Tasali suggested. Fur-
thermore, a vicious cycle might occur in
individuals with established diabetes of
OSA leading to hyperglycemia, requiring
increasing glucose-lowering treatment,
which could in turn cause weight gain
and worsen the sleep apnea. Given this
perspective, she remarked upon the
weight gain in the intensive glycemic
treatment group of the Action to Control
Cardiovascular Risk in Diabetes (AC-
CORD) study and suggested that a com-
ponent of their increased mortality might
be related to unrecognized development
of OSA.
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